{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:07:18Z","timestamp":1794272838991,"version":"4.9.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.urolonc.2021.09.022","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T17:33:49Z","timestamp":1636133629000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Critical shortage in BCG immunotherapy: How did we get here and where will it take us?"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-5412","authenticated-orcid":false,"given":"Michael","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodie","family":"Chislett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5145-6783","authenticated-orcid":false,"given":"Damien","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.09.022_bib0001","first-page":"221","article-title":"Die Aetiologie der Tuberculose","volume":"19","author":"Koch","year":"1882","journal-title":"Berliner Klinische Wochenschrift"},{"key":"10.1016\/j.urolonc.2021.09.022_bib0002","unstructured":"Calmette A. L'infection bacillaire et la tuberculose chez l'homme et chez les animaux: processus d'infection, et de defense, \u00e9tude biologique et exp\u00e9rimentale. 1922."},{"key":"10.1016\/j.urolonc.2021.09.022_bib0003","first-page":"97","article-title":"Cancer and tuberculosis","volume":"9","author":"Pearl","year":"1929","journal-title":"Am J Hygeine"},{"issue":"Suppl 5","key":"10.1016\/j.urolonc.2021.09.022_bib0004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.urolonc.2021.09.022_bib0005","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7597","key":"10.1016\/j.urolonc.2021.09.022_bib0006","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(69)92648-8","article-title":"Active immunotherapy for acute lymphoblastic leukaemia","volume":"1","author":"Mathe","year":"1969","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.urolonc.2021.09.022_bib0007","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jama.1974.03230440046032","article-title":"Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine","volume":"229","author":"Silverstein","year":"1974","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.urolonc.2021.09.022_bib0008","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.09.022_bib0009","first-page":"8788","article-title":"BCG: a throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy","volume":"24","author":"Morales","year":"2017","journal-title":"Can J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.09.022_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.23736\/S0393-2249.18.03309-X","article-title":"Bacillus Calmette-Gu\u00e9rin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know","volume":"71","author":"Moschini","year":"2019","journal-title":"Minerva Urol Nefrol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.09.022_bib0011","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","article-title":"Bacillus Calmette-Guerin immunotherapy for genitourinary cancer","volume":"112","author":"Gandhi","year":"2013","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2021.09.022_bib0012","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.09.022_bib0013","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2021.09.022_bib0014","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2021.09.022_bib0015","article-title":"Merck remains committed to producing TICE\u00ae BCG for the treatment of certain forms of bladder cancer","author":"Merck","year":"2019","journal-title":"Merck Newsroom"},{"issue":"3","key":"10.1016\/j.urolonc.2021.09.022_bib0016","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus calmette-guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.09.022_bib0017","unstructured":"AUA. BCG Shortage Information. https:\/\/wwwauanetorg\/about-us\/bcg-shortage-info. 2019."},{"issue":"3","key":"10.1016\/j.urolonc.2021.09.022_bib0018","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.urolonc.2021.09.022_bib0019","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring access to injectable generic drugs - The case of intravesical BCG for bladder cancer","volume":"376","author":"Davies","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.urolonc.2021.09.022_bib0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.09.022_bib0021","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921004476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921004476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:07Z","timestamp":1761042187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921004476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1078143921004476"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.09.022","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical shortage in BCG immunotherapy: How did we get here and where will it take us?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}